ACE Inhibitors Market Forecast 2025-2034: Evaluating Growth Factors, Segments, and Emerging Trends

What combination of drivers is leading to accelerated growth in the ace inhibitors market?
The rise in hypertension disorders can be expected to propel the growth of the ACE inhibitors market in the future. Hypertension, more commonly known as high blood pressure, is a condition where the pressure in the blood vessels is abnormally high. Angiotensin-converting enzyme inhibitors, commonly known as ACE inhibitors, belong to a set of drugs that are employed to manage and regulate hypertension. They work by easing the blood vessels, leading to a decrease in blood pressure and better blood circulation. For instance, data from March 2023 by the World Health Organization, a United Nations specialty organization based in Switzerland, showed that about 1.28 billion adults between 30 and 79 worldwide suffered from hypertension, with two-thirds of them living in low-to-middle income countries. In the past three decades, hypertension has affected an additional 650 million people between 30 and 79 years old. It is estimated that 46% of adults with hypertension lack awareness about their health condition as they have not been diagnosed. In the last 30 years, the population of adults aged 30-79 having hypertension has risen by 650 million. Roughly 46% of people with hypertension are ignorant of their state because they are undiagnosed. Consequently, the escalating prevalence of hypertension disorders is stimulating the growth of the ACE inhibitors market.

Get Your ACE Inhibitors Market Report Here:
https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

What is the projected compound annual growth rate (CAGR) of the ace inhibitors market from 2025 to 2034, and what factors influence it?
Over the past few years, the market size for ACE inhibitors has seen a consistent rise. The market, which is currently valued at $7.15 billion in 2024, is expected to grow to $7.48 billion by 2025, indicating a compound annual growth rate (CAGR) of 4.6%. The surge during the recorded period can be credited to factors such as increased incidence of cardiovascular ailments, rising aging populace, clinical efficiency and security profile, escalating diabetes prevalence, along with regulatory approval and guidelines.

The ACE inhibitors market is anticipated to witness significant expansion in the coming years, increasing to $9.6 billion by 2029 with a compound annual growth rate (CAGR) of 6.4%. A major factor attributing to the growth during the forecast period includes the rising global prevalence of cardiovascular diseases, extension of hypertension treatment guidelines, progress in combined therapies, emphasis on heart failure management, and enhanced awareness and accessibility of healthcare. The main trends projected to be observed during this period encompass focus on safeguarding the kidneys, preference towards renin-angiotensin system inhibitors, generic competition and pricing dynamics, patient-oriented strategies in healthcare, regulatory revisions, and safety priorities.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

How are the latest trends influencing the growth of the ace inhibitors market?
The primary trend in the ACE inhibitors market that's gaining traction is the focus on product innovations. Major companies in this industry are channeling their efforts towards crafting innovative products in order to consolidate their market position and gain a competitive edge. Contextually, Travere Therapeutics, an American biopharmaceutical company, in February 2023, received FDA approval for FILSPARI (sparsentan), a pioneering non-immunosuppressive treatment for patients diagnosed with IgA nephropathy (IgAN). The approved treatments encompass systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medications, inclusive of angiotensin-receptor blockers (ARBs). FILSPARI is exceptional as it is the sole non-immunosuppressive therapy that has received approval. This once-daily orally taken medicine is tailored to treat adult patients with primary IgAN who are at high risk of rapid disease progression, typically characterized by a UPCR under 1.5 g/g and proteinuria.

What are the major segments of the ace inhibitors market and their role in driving growth?
The ACE inhibitors market covered in this report is segmented -

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents
2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs
3) By Dosage Form: Oral Tablets, Oral Solutions
4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications
5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:
1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril
2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril
3) By Phosphonate-Containing Agents: Fosinopril

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10671

Which regions are key players in the growth of the ace inhibitors market?
North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the key firms paving the way for growth in the ace inhibitors market?
Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy's Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

What Is Covered In The ACE Inhibitors Global Market Report?

• Market Size Forecast: Examine the ace inhibitors market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the ace inhibitors market for a structured understanding.
• Key Players Overview: Analyze major players in the ace inhibitors market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the ace inhibitors market.
• Segment Contributions: Evaluate how different segments drive overall growth in the ace inhibitors market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the ace inhibitors market.
• Industry Challenges: Identify potential risks and obstacles affecting the ace inhibitors market.
• Competitive Landscape: Review strategic developments in the ace inhibitors market, including expansions, agreements, and new product launches.

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.